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Mild traumatic brain injury (mTBI) is the subject of increasing public health 
concern. Symptoms following mTBI, as well as risk factors for prolonged recovery, have 
been well-described. The physiological mechanisms behind these physical symptoms, 
and time course of recovery after injury, however, remain largely unknown. The purpose 
of this dissertation, therefore, was to assess the acute and chronic impact of mTBI on 
motor cortex function and associated neurotransmitter concentrations. A secondary goal 
of this dissertation was to establish the relationship between motor cortex function and 
the risk factors of female sex and APOE genotype in acute and chronic mTBI patients.  
Motor cortex function and neurotransmitter concentrations were assessed using 
transcranial magnetic stimulation and magnetic resonance spectroscopy, respectively. It 
was found that excitability, as assessed by the amplitude of the motor evoked potential 
(MEP), was lower in the Chronic group (participants with chronic symptoms from mTBI, 
lasting at least 3 months post-injury) compared to the control groups (p=0.02), but no 
differences in glutamate, the primary excitatory neurotransmitter, were found in the 
motor cortex between any group (p=0.93) or over time acutely following mTBI (p=0.70). 




was higher in individuals acutely following mTBI (within 72 hours of mTBI diagnosis) 
and throughout two months of recovery (p=0.02), but no differences in GABA, the 
primary inhibitory neurotransmitter, were found in the motor cortex between any group 
(p=0.06) or over time following acute mTBI (p=0.57). There were no differences in MEP 
amplitude, CSP duration, glutamate concentration, or GABA concentration between 
males and females, or carriers of the apoε4 allele at any time point following mTBI 
(p≥0.10). 
This dissertation represents a compilation of studies which are among the first to 
document motor cortex excitability, intracortical inhibition, glutamate, and GABA 
concentrations in individuals with acute and chronic symptoms from mTBI. The data 
suggest a possible functional change longitudinally following mTBI, despite an expected 
neurochemical profile. Results from these studies suggest that humans may not follow the 
same neurometabolic timeline as the rodent model following mTBI. 
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 Traumatic brain injury (TBI) is classified as an injury to the brain caused by 
mechanical force acting on the body (McCrory et al. 2013). This type of injury can lead 
to cognitive symptoms such as impaired memory, confusion, and difficulty concentrating 
(Cantu 2006) as well as deficits in physical function such as slow movement speed (Gray 
et al. 1998), impaired balance (Chou et al. 2004), and slowed reaction time (Howell et al. 
2013a). An estimated 5.3 million Americans currently live with a TBI-related disability, 
and for some, the effects may be permanent (Center for Disease Control and Prevention 
2010). Numerous factors have been suggested to contribute to recovery from mild 
traumatic brain injury (mTBI), and among the most extensively studied include age, sex, 
history of mTBI, and presence of the apolipoprotein E (APOE) genotype (Meehan et al. 
2011; McClincy et al. 2006; Scopaz and Hatzenbuehler 2013; Eramudgolla et al. 2014; 
Broshek et al. 2005; Tierney et al. 2010). The physiology of TBI has been studied in 
animal models (Giza and Hovda 2001), but has not been extensively explored in humans. 
The overall goal of this dissertation is to assess the acute and chronic impact of mTBI on 
motor cortex function and associated neurotransmitter concentrations. A secondary goal 
of this dissertation is to establish the relationship between motor cortex function and 
APOE genotype in individuals who have suffered an mTBI.  
Structural changes within the brain after an mTBI are not always evident with 
imaging techniques, making it difficult to identify and treat areas affected by the injury 
(van der Naalt et al. 1999; Voller et al. 1999).  Recovery from mTBI, therefore, is 
commonly assessed by neuropsychological tests, the majority of which typically return to 
2 
baseline values within two weeks post-injury (Hinton-Bayre and Geffen 2002). It has 
been consistently demonstrated, however, that even in the absence of neuropsychological 
deficits, motor deficits such as gait instability (Slobounov et al. 2007), slow movement 
speed (Gray et al. 1998; De Beaumont et al. 2009) impaired balance (Chou et al. 2004), 
and slowed reaction time (Howell et al. 2013b; Halterman et al. 2006) can persist months 
to years after initial injury (Gray et al. 1998; Chou et al. 2004). Howell et al. (2013a) 
found that adolescents with mTBI demonstrated higher levels of medial/lateral 
displacement during an attention-divided gait task at 72-hours post-injury, a deficit that 
did not resolve to control levels throughout two months of testing. Similarly, adults tested 
within 48 hours of injury have also demonstrated altered gait, as evidenced by slower 
walking speed during dual-task walking (Catena et al. 2009). Although such motor 
impairments have been cited as early indicators of chronic difficulties associated with 
brain injury (Rabadi and Jordan 2001), the mechanisms leading to these persistent motor 
deficits remain largely unknown.  
Widespread changes in metabolite concentration are a likely candidate for 
explaining physical symptoms, as well as cognitive and motor deficits recorded in 
humans post-mTBI. Changes in metabolite concentration begin immediately in the brain 
after a mechanically-induced injury to the head or neck. Researchers have used the term 
"Neurometabolic Cascade" to describe these changes in neurotransmitter concentration 
and the effects each subsequent phase has on the next (Giza and Hovda 2001). Acutely 
after injury, the brain experiences a state of massive excitation caused by an 
indiscriminate release of excitatory neurotransmitters such as glutamate. Glutamate 
transport decreases following mTBI, allowing excess glutamate to stay in the synapse and 
3 
prolong the excitotoxic environment in the brain. This acute, excitatory phase resolves 
fairly quickly in the animal model as the sodium/potassium pumps work to restore 
homeostasis (Giza and Hovda 2001). A compensatory "spreading depression" phase 
follows the acute excitatory phase, leading to a global decrease in glutamate and an 
energy crisis as ATP is used by the sodium/potassium pump. Studies show that neurons 
injured following mTBI demonstrate a reduction in dendrite length and inhibited 
neuronal signaling, suggesting that mTBI may lead to a change in the 
excitatory/inhibitory balance post-injury (Brizuela et al. 2017). Although glutamate levels 
resolve within 10
 
minutes post-injury in a rodent model (Giza and Hovda 2001), this 
timeline cannot be directly applied to metabolite recovery in a human following mTBI. 
Non-invasive techniques such as transcranial magnetic stimulation (TMS) and magnetic 
resonance spectroscopy (MRS) indirectly and directly quantify neurotransmitter activity 
in humans and provide mechanistic insight into motor and cognitive functional decline 
and recovery post-injury. 
Transcranial magnetic stimulation (TMS) and magnetic resonance spectroscopy 
(MRS) studies provide non-invasive techniques that can be used to assess functional 
changes and neurotransmitter concentrations in the primary motor cortex following 
mTBI. Lower cortical excitability, as assessed by the TMS measure resting motor 
threshold (RMT), has been demonstrated in individuals acutely post-mTBI (Chistyakov 
et al. 2001; Henry et al. 2010). Using TMS, it has also been demonstrated that 
intracortical inhibition, as assessed by the duration of the cortical silent period (CSP), is 
augmented in individuals with mTBI (De Beaumont et al. 2009), and recent findings 
4 
suggest that this greater level of inhibition does not recover by two months post-injury 
(Miller et al. 2014).  
In addition to TMS measures of cortical excitability and inhibition, quantities of 
the excitatory neurotransmitter glutamate and the inhibitory neurotransmitter GABA, as 
obtained by proton magnetic resonance spectroscopy (
1
H-MRS), provide further insight 
into motor, cognitive, and physiological consequences of mTBI. While TMS provides 
useful information regarding cortical excitability and inhibition, 
1
H-MRS can directly and 
non-invasively evaluate relative concentrations of neurotransmitters thought to modulate 
TMS measures of cortical excitability and inhibition in specific brain areas of interest. 
Using this technique, it has been shown that, despite normal neuropsychological scores 
and anatomical MRI results, athletes with mTBI have altered neurometabolic profiles in 
comparison to controls 1-6 days post-injury (Henry et al. 2010). Specifically, these 
athletes were reported to have lower levels of glutamate, the primary excitatory 
neurotransmitter, in the primary motor cortex (M1). It has been suggested that physical 
symptoms of mTBI including headache, sensitivity to light, dizziness, and nausea may be 
explained by these alterations of metabolite concentration within the brain acutely post-
injury (Henry et al. 2010).  
An individual's physiological response to mTBI is often unpredictable, as there is 
a high degree of inter-individual variability in symptoms experienced (Guskiewicz 2001). 
While symptoms recover within approximately 2 weeks for most individuals (Hinton-
Bayre and Geffen 2002), 10-15% of the population with mTBI will continue to 
experience symptoms chronically (Ruff et al. 1996). While acutely-injured individuals 
have consistently demonstrated motor deficits in the absence of neuropsychological 
5 
deficits, (Gray et al. 1998; Chou et al. 2004; Slobounov et al. 2007; Howell et al. 2013b) 
similar assessments in individuals with chronic symptoms have not been made. 
Therefore, little is known about the physiological characteristics of chronic mTBI and 
how they compare with characteristics of acute injury. Further, it is not known how these 
prolonged deficits relate to individual risk factors, such as Apolipoprotein E (APOE) 
genotype.  
Recent mTBI studies have focused on the predictive properties of specific genes, 
most notably, the APOE gene. The APOE gene is located on the long arm of chromosome 
19 and provides the template for creating a protein (apoE) that plays a vital role in 
transporting cholesterol to neurons. This protein is mainly produced by astrocytes and 
microglia in the central nervous system (Lawrence et al. 2015). The apoE protein is also 
critically involved with repair of the neuronal cell membrane (Mahley 2016), dendrite 
and synapse formation (Nathan et al. 1994), and the maintenance of calcium homeostasis 
within the neuron (Muller et al. 1998), all processes essential to recovery after mTBI. 
There are three main isoforms, or, versions, of APOE inheritable by humans. The rarest 
form, ε2, occurs in roughly 7% of the population, while the ε3 and ε4 alleles occur at a 
frequency of 78% and 15% respectively (Roses 1996). 
 The ε4 allele has received much attention from TBI researchers in recent years 
and is associated with poorer outcome after TBI, including greater severity of injury 
(Jiang et al. 2011), worse Glasgow Coma Scale scores (Teasdale et al. 1997), lower 
motor scores on the Functional Independence Measure (Lichtman et al. 2000), and 
cognitive impairment in elderly and adolescent populations (Eramudgolla et al. 2014; 
Lawrence et al. 2015). Possession of one or more ε4 alleles is associated with a 10-fold 
6 
increased risk of mTBI history in athletes (Tierney et al. 2010) and, despite the relative 
rarity of the ε4 allele in nature, this isoform is overrepresented in chronic traumatic 
encephalopathy and chronic TBI populations (McKee et al. 2009). The detrimental 
effects of the ε4 allele tend to occur in a dose-dependent fashion, meaning that the 
highest risks and poorest outcomes occur in those ε4 homozygotes who possess two ε4 
alleles (ε4ε4 genotype) (Guo et al. 2000). It has been suggested that the ε4 allele produces 
a less efficient form apoE protein in astrocytes and microglia, and its inadequacy is 
exaggerated in an environment like TBI where its role is more heavily required for 
recovery (Lawrence et al. 2015). 
Animal studies provide insight into the role of APOE genotype and levels of 
excitatory and inhibitory neurotransmitter concentration in the cortex. Chen et al. (2010) 
observed that ε4 carrier mice displayed reduced glutamate receptor function, while 
Dumanis et al., (2013) used magnetic resonance spectroscopy and found decreased global 
concentrations of the excitatory neurotransmitter glutamate and increased levels of 
glutamine in the brains of ε4 carrier mice. In this study, concentrations of GABA, an 
inhibitory neurotransmitter, were not different among ε4 carriers. However, to our 
knowledge, similar assessments of glutamate, GABA and ε4 carrier status have not been 
made in humans. Such information would provide valuable insights into risk factors for 
chronic mTBI and the physiological consequences. 
The overall goal of this dissertation is to assess the acute and chronic impact of 
mTBI on motor cortex function and associated neurotransmitter concentrations. A 
secondary goal of this dissertation is to establish the relationship between motor cortex 
function, sex, and APOE genotype in acute and chronic mTBI patients. Such information 
7 
will provide insight into potential precursors for brain injury and prolonged recovery 
from mTBI. 
Specific aim 1 
The aim of the first study was to determine the level of excitability and inhibition 
in the motor cortex of individuals with acute and chronic symptoms from mTBI, 
compared with healthy controls.  
Hypothesis 1.1 
Based on evidence from the Neurometabolic Cascade, acutely-injured individuals 
will experience higher levels of motor cortex excitability and higher levels of intracortical 
inhibition than healthy control participants.  
Hypothesis 1.2 
 Individuals with chronic symptoms from mTBI will experience similar levels of 
motor cortex excitability and higher levels of intracortical inhibition compared with 
healthy control participants. 
Specific aim 2 
The aim of the second study was to determine the concentrations of excitatory and 
inhibitory neurotransmitter in individuals with acute and chronic symptoms from mTBI 
compared with healthy controls.  
Hypothesis 2.1 
Based on evidence from the Neurometabolic Cascade, acutely-injured individuals 




 Individuals with chronic symptoms from mTBI will have similar levels of 
glutamate in the motor cortex, but elevated levels of GABA compared to healthy control 
participants. 
Specific aim 3 
The aim of the final study was to determine if the risk factors of female sex and 
apoε4 genotype will contribute to motor cortex function following mTBI. 
Hypothesis 3.1 
 Females with mTBI will report higher symptom scores than males with mTBI. 
Hypothesis 3.2 
 Females with mTBI will have similar levels of motor cortex excitability and 
inhibition compared to males with mTBI. 
Hypothesis 3.3 
 There will be a higher proportion of ε4 carriers in the group with chronic 
symptoms from mTBI compared to the allele frequency of ε4 in the general population. 
Hypothesis 3.4 
Apoε4 carriers will have lower levels of excitability and similar levels of 
intracortical inhibition than non-carriers in all groups. 
Hypothesis 3.5 
Apoε4 carriers will have lower levels of glutamate and similar levels of GABA 
than non-carriers in all groups. 
Study participants 
 Individuals with mTBI who participated in the studies outlined in this dissertation 
were diagnosed with concussion (a form of mTBI) by specialized health professionals 
9 
(certified athletic trainer or physician) at the time of injury. All injuries met the definition 
of concussion provided by the 4
th
 International Consensus Statement on Concussion in 
Sport (McCrory et al. 2013). ImPACT post-injury tests were used as a diagnosis for 
individuals who had completed baseline ImPACT testing prior to mTBI.  
 Participants were excluded if they had (i) a history of two or more mTBIs or an 
mTBI within a year prior to testing, (ii) loss of consciousness for more than 1 minute 
(mTBI group), (iii) history of cognitive deficiencies independent of the injury, such as 
memory loss or difficulty concentrating, (iv) history of attention deficit hyperactivity 
disorder, neurological impairment, musculoskeletal impairments or seizures or (v) 
contraindications to the use of transcranial magnetic stimulation (TMS) or magnetic 
resonance imaging (MRI) including medications that could affect neurotransmitter 
function. All procedures used in this investigation were reviewed and approved by the 
Institutional Review Board of the University of Oregon, and participants provided 
written, informed consent prior to beginning study procedures. 
 Table 1.1 describes the type of mTBI (sports- or non-sports-related) sustained by 
individuals in the Acute and Chronic mTBI groups. Sports-induced mTBIs were 
sustained during play in the following sports: rugby (6), soccer (6), basketball (2), 
ultimate Frisbee (2), wrestling (1), hockey (1), and snowboarding (1).  
Table 1.1. MTBI Type 
 Acute Chronic 
Sports 16 3 
Non-sports 13 10 
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Symptoms scores were obtained from participants at their first visit to the 
laboratory (within 72 hours for acutely-injured participants). Various symptom 
inventories were obtained from participants, including a symptom inventory adopted 
from McCrory et al (2013), a survey adapted from the Post-Concussive Symptom Score 
section of the ImPact test and from the SCAT3 (Broglio et al. 2007) and the Rivermead 
Post-Concussion Symptoms Questionnaire (King et al. 1995) For all inventories used, the 
Acute and Chronic groups reported more symptoms than their respective control groups 
(p≤0.01). 
A total of 35 individuals (5 Control, 7 Acute, 18 Chronic Control, and 5 Chronic) 
participated in all three studies included in this dissertation. Twenty-seven (11 Control, 
13 Acute, 2 Chronic Control, and 1 Chronic) participated in study 1 only. Seven (1 
Acute, 5 Control, and 1 Chronic Control) participated in studies 1 and 2 only. Fifteen (7 
Acute, 6 Control, 2 Chronic Control) participated in studies 1 and 3 only. One (Chronic) 
participated in study 2 only, and one (Chronic) participated in studies 2 and 3 only.  
Flow of dissertation 
Chapter II focuses on the post-mTBI recovery of motor cortex function as 
assessed by TMS. Chapter III discusses the presence of glutamate and GABA in the 
motor cortex following mTBI. Chapter IV evaluates the TMS and MRS data according to 
apoε4 carrier status. 
Chapters II and III include previously published co-authored material. Portions of 
Chapters II and III were previously published in Medicine and Science in Sports and 




MOTOR CORTEX FUNCTION FOLLOWING MTBI 
Some material from this chapter was previously published in volume 49, issue 6 
of Medicine and Science in Sports and Exercise in June 2017. Alia Yasen contributed to 
the concept of the study, recruited participants, collected and analyzed data, and helped 
prepare the initial manuscript. Dr. Anita Christie contributed to the concept of the study, 
aided in the interpretation of the data, and critically reviewed and revised the manuscript.  
Introduction 
Mild traumatic brain injury (mTBI) has been described as a diffuse injury that can 
impact both cognitive and motor function (Howell et al. 2013a; Howell et al. 2013b; 
Miller et al. 2014; Parker et al. 2007). Common cognitive symptoms include, but are not 
limited to, confusion, difficulty focusing attention, impaired memory and reduced visual 
processing speed (Cantu 2006; Parker et al. 2007; Guskiewicz et al. 2003). Recovery 
from sport-related mTBI, in particular, is typically assessed using computerized 
neurocognitive testing techniques and is reported to occur within 10 days post-injury 
(Guskiewicz et al. 2003; Bleiberg et al. 2004). A growing body of literature, however, 
suggests that even in the absence of neurocognitive deficits, motor impairments such as 
reduced movement speed, and difficulties with gait and balance control, can persist for up 
to two months post-injury (Gray et al. 1998; De Beaumont et al. 2009; Miller et al. 2014; 
Howell et al. 2015). Although such motor impairments have been cited, in some cases, as 
early indicators of chronic difficulties associated with brain injury (Rabadi and Jordan 
2001), the underlying mechanisms of these functional deficits are not yet fully 
understood.  
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Mild traumatic brain injury is accompanied acutely by alterations in 
neurotransmitter release as well as ionic and metabolic changes (Giza and Hovda 2001) 
that can impact cortical neuronal function. Using transcranial magnetic stimulation 
(TMS), a non-invasive method of probing cortical function, a growing body of literature 
(De Beaumont et al. 2009; Miller et al. 2014; De Beaumont et al. 2007; Tremblay et al. 
2011) suggests that motor cortex function is affected by TBI. Specifically, inhibition, as 
measured by the cortical silent period, is increased (De Beaumont et al. 2009; Miller et al. 
2014; De Beaumont et al. 2007; Tremblay et al. 2011) and is related to slowness of 
movement up to 30+ years post-injury (De Beaumont et al. 2009). These results suggest 
that high levels of cortical inhibition may be a prime mechanistic candidate for the motor 
deficits observed acutely and up to two months of recovery following mTBI (Catena et 
al. 2009; Parker et al. 2007; Parker et al. 2006) 
The purpose of this study was to determine the level of excitability and inhibition 
in the motor cortex of individuals with acute and chronic symptoms from mTBI, 
compared with healthy controls. It was hypothesized that acutely-injured individuals 
would experience higher levels of motor cortex excitability and higher levels of 
intracortical inhibition than healthy control participants, and that individuals with chronic 
symptoms from mTBI would experience similar levels of motor cortex excitability and 
higher levels of intracortical inhibition compared with healthy control participants.  
Materials and methods 
Participants 
 Ninety-one individuals were assigned to one of four groups: (i) without history of 
mTBI (Control, n=27, 15 females), (ii) within 72-hours of diagnosis of mTBI (Acute, 
13 
n=29, 15 females), (iii) with history of mTBI and no remaining symptoms (Chronic 
Control, n=24, 11 females), and (iv) with chronic symptoms from mTBI, lasting at least 3 
months post-injury (Chronic, n=13, 6 females). All participants provided written 
informed consent and were asked to complete a brief medical history and TMS safety 
screening questionnaire to determine eligibility to participate before enrollment. 
Exclusion criteria for all participants included: 1) history of cognitive 
deficiencies, such as permanent memory loss or concentration abnormalities (unrelated to 
the mTBI injury), 2) loss of consciousness from the mTBI lasting more than one minute, 
3) history of attention deficit hyperactivity disorder, or 4) contraindications to the use of 
TMS (Rossi et al. 2011).  All procedures were reviewed and approved by the University 
of Oregon Institutional Review Board prior to any data collection. Three individuals (two 
from the Chronic group and one from the Chronic Control group) were excused from this 
portion of the study due to contraindications with TMS.  
Measurement schedule 
 Each participant completed at least one testing session, during which measures of 
motor cortex excitability and inhibition were obtained using TMS. Participants in the 
Acute group were tested within 72 hours of sustaining their mTBI (±2 days). Participants 
in the Chronic group were tested an average of 4.0 years post-injury (±2.0 years), and 
those in the Chronic Control group were tested an average of years 3.9 years post-injury 
(±2.8 years).    
 A total of 9 Acute and 14 Control participants came in for additional testing. 
These acutely-injured individuals came in for testing within 72 hours of injury and again 
14 
at 1 week, 2 weeks, 1 month, and 2 months post-injury. The 14 Control participants 
followed a similar timeline, once recruited. 
Electromyography (EMG) 
 A preamplified bipolar, Ag-AgCl EMG electrode (DE-2.1, Delsys Inc., Boston, 
MA), with an inter-electrode distance of 1 cm was placed over the first dorsal 
interosseous (FDI) of the dominant hand. This electrode was connected to a portable 
amplifier (Delsys Inc., Boston, MA), which further amplified and band-pass (20-450 Hz) 
filtered the EMG signal. A ground electrode was secured to the posterior aspect of the 
distal ulna. The EMG signal was sampled at 5 kHz with a 16-bit A/D converter (NI USB-
6251, National Instruments, Austin, TX).  
Motor evoked potential (MEP) and Cortical Silent Period (CSP) 
 TMS was performed using a flat, 70-mm figure-of-eight coil positioned over the 
optimal site of the contralateral motor cortex to elicit motor evoked potentials (MEP) in 
the dominant FDI. The optimal site was defined as the position that yielded the largest 
MEP consistently. Once the optimal site was located, the resting motor threshold (RMT) 
was determined as the lowest intensity required to evoke a response of at least 50µV in at 
least 5 out of 10 trials (Orth and Rothwell 2004; Werhahn et al. 1999). Eight cortical 
silent periods were then evoked by single-pulse stimulations delivered at 120% of the 
RMT while participants maintained an isometric of the dominant FDI at 50% of their 
maximal voluntary contraction (MVC). Visual feedback, including a target line at 50% 
MVC, was provided to the participants and the experimenter ensured that participants had 
reached the target level of EMG prior to providing the TMS pulse. A rest period of 30 
seconds was provided between stimulations.  
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 Motor cortex excitability was assessed through the peak-to-peak amplitude of the 
active MEP (Figure 2.1, horizontal lines). Inhibition was assessed through the CSP 
duration and was manually identified for each trial as the time between the end of the 
MEP and the resumption of voluntary EMG activity (Figure 2.1, shaded area). All trials 
were analyzed, using a custom-written MATLAB (Mathworks Inc., Natick, MA) 
program, by the same trained investigator, who was blinded to the participants’ group at 
the time of data analysis. Such manual selection of EMG onset times has been shown to 
have similar reliability as automated procedures (Ives and Wigglesworth 2003). 
 
Figure 2.1. Sample recording of evoked responses. Excitability was assessed through 
the peak-to-peak amplitude of the MEP (horizontal lines). Inhibition was assessed 
through the cortical silent period (CSP) duration (shaded area). 
 
Statistical analysis 
 Two-factor repeated measures ANOVAs (mTBI group, time) were calculated for 
the sub-set of Acute and Control participants who came to lab for multiple days of 
testing. One-factor (mTBI group) ANOVAs were performed to assess differences in MEP 
amplitude and CSP duration between all four groups. Where necessary, post-hoc pairwise 




 Participant characteristics are presented in Table 2.1. There were no group 
differences in height (p=0.10) or weight (p=0.2), but the Chronic group was significantly 
older than the other three groups (p=0.003). 
Table 2.1. Participant Characteristics 
 Control Acute Chron. Control Chronic        p 
n 27 (15 f) 29 (15 f) 20 (9 f) 11 (6 f)  
Age (years) 21.6 ± 3.9 21.0 ± 3.8 20.2 ± 2.1 26.7 ± 9.5 0.003 
Height (cm) 169.5 ± 10.2 174.4 ± 11.1 173.1 ± 8.3 164.6 ± 7.3 0.10 
Mass (kg) 65.0 ± 10.0 73.2 ± 14.2 71.7 ± 14.3 62.0 ± 12.4 0.20 
 
Motor evoked potential (MEP) 
 There was no group difference in MEP amplitude between the subset of Acute 
and Control participants who completed 5 sessions of testing over a 2-month period 
(p=0.20, Figure 2.2). There was no significant effect of time on MEP amplitude (p=0.10) 
and there was no group by time interaction (p=0.24). 
For the comparison between all four groups, the MEP amplitude was significantly 
different between groups (p=0.05, Figure 2.3). Post-hoc comparisons revealed that the 
Chronic group had a significantly smaller MEP amplitude compared to the Control 
(p=0.02) and Chronic Control (p=0.02) groups, indicating lower cortical excitability in 
the Chronic group. Data from three participants in the Chronic Control group were found 
to be outliers and removed from the analysis (data from 20 total Chronic Control 
participants were used in this analysis).  
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Figure 2.2. MEP amplitude across time. There was no effect of group (p=0.20) or time 
(p=0.10) on MEP amplitude over the course of recovery. There was no interaction 
between group and time (p=0.24). 
 
 
Figure 2.3. MEP amplitude group comparison. The MEP amplitude was significantly 
different between groups (p=0.05). Post-hoc comparisons revealed that the Chronic group 
had a significantly smaller MEP amplitude compared to the Control (p=0.02) and 
Chronic Control (p=0.02) groups. 
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Cortical silent period (CSP) 
 For the subset of participants who were tested across two months, the CSP 
duration was significantly longer in the Acute group compared to controls (p=0.02, 
Figure 2.4). Post-hoc analyses revealed the CSP duration was significantly longer in the 
Acute group at 72-hours, 1 month, and 2 months post-injury. There was no significant 
effect of time on CSP duration (p=0.20). There was a significant group-by-time 
interaction (p≤0.001) with longer CSP durations in the Acute group compared to controls 
at 72 hours (p=0.03), 1 month (p=0.003), and 2 months post-injury (p=0.005).  
 
Figure 2.4. CSP duration across time. The CSP duration was significantly longer in the 
Acute group compared to controls (p=0.02), specifically, at 72-hours, 1 month, and 2 
months post-injury. There was no significant main effect of time on CSP duration 
(p=0.20) There was a significant group-by-time interaction (p≤0.001) with longer CSP 




The comparison between all four groups indicated that the CSP duration was not 
significantly different between groups (p=0.14, Figure 2.5) indicating no effect of mTBI 
on intracortical inhibition.  
 
Figure 2.5. CSP duration group comparison. The CSP duration was not different 
between groups (p=0.14). 
 
Discussion 
 The purpose of this investigation was to determine the level of excitability and 
inhibition in the motor cortex of individuals with acute and chronic symptoms from 
mTBI, compared with healthy controls. The results demonstrated that individuals with 
chronic symptoms from mTBI had lower MEP amplitudes than individuals in the two 
control groups, indicating lower cortical excitability in the Chronic group. No differences 
in intracortical inhibition as assessed by the cortical silent period were observed between 




It was originally hypothesized that the Acute group would display higher levels of 
cortical excitability compared with the control group at 72 hours post-injury. We found 
that excitability, as assessed by the MEP amplitude, was not different between the subset 
of Acute and Control participants at any point throughout the 2-month recovery period. 
While we did not report any differences in MEP amplitude in our Acute group, this 
finding is consistent with other studies that have also reported no differences in cortical 
excitability 72-hours to 2-weeks post-mTBI (Miller et al. 2014; De Beaumont et al. 
2007). In the rodent model, the acute, excitatory phase of the Neurometabolic Cascade 
following mTBI tends to resolve fairly quickly (Giza and Hovda 2001). While the time 
course of this cascade is unknown in humans, it is possible that the initial release of 
excitatory neurotransmitters in the brain following mTBI may resolve in the human brain 
by 72-hours post-injury. It is possible that differences in excitability in our Acute group 
were missed because too much time had elapsed between the initial injury and the data 
collection. 
To our knowledge, this is the first study to report differences in cortical 
excitability in individuals with chronic symptoms from mTBI compared to healthy 
individuals. Results from this study indicated that chronically-symptomatic individuals 
showed smaller MEP amplitudes, and therefore, lower cortical excitability, than those in 
the two control groups, but similar levels of cortical excitability to those with acute 
mTBI. Based on animal literature regarding the relative timeline of metabolic changes in 
the brain post-mTBI, it was originally hypothesized that individuals with chronic 
symptoms from mTBI would be outside the window of time for excitotoxic changes to 
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occur in the brain, and therefore, show no differences in cortical excitability compared to 
control groups. Following the initial stage of the Neurometabolic Cascade, however, the 
brain enters a “spreading depression” phase that may have longer-lasting effects than the 
acute excitotoxic phase (Giza and Hovda 2001). It is possible that individuals whose 
symptoms do not recover from mTBI after months or years may still be in this altered 
“depressed” stage of metabolic and ionic imbalance.  
 It should be addressed that the average participant in the Chronic group was 
significantly older (26.7 years) than participants in the other three groups (< 22 years). 
Eisen et al., (1991) previously reported smaller MEP amplitudes in older individuals, but 
the average age of participants in this study was 63 years. Although participants in the 
Chronic group for this study were, on average, older, the average age was still well below 
what is considered to be an “elderly” or “older adult” population. Therefore, while the 
difference in age may have impacted the MEP results in this study, it is unlikely.  
Inhibition 
 Based on previous studies documenting higher levels of intracortical inhibition 
both acutely and longer-term following mTBI (Miller et al. 2014; De Beaumont et al. 
2007), it was hypothesized that both the Acute and Chronic groups would have higher 
levels of intracortical inhibition. Similar to this previous research, we found that the CSP 
duration was longer in the subset of Acute and Control participants during 2 months of 
recovery. When using the acute, 72-hour time point as a comparison, however, we did not 
report any difference in CSP duration between all four participant groups. Although this 
comparison was not statistically different, the CSP duration was slightly higher in the 
Acute and Chronic groups compared to the two control groups, following a similar trend 
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as the longitudinal data from the subset of participants who came for multiple days of 
testing. The addition of more Acute and Control participants as well as the Chronic 
Control and Chronic groups introduced slightly more variability into the CSP data, which 
may explain why the difference in CSP duration did not reach statistical significance. It is 
also possible that additional factors may be responsible for TMS measures of inhibition, 
such as concentrations or availability of inhibitory neurotransmitter. To our knowledge, 
no studies have reported levels of intracortical inhibition in individuals with chronic 
symptoms from mTBI. Although our Chronic group did not demonstrate longer CSP 
durations than their control group, data from the longitudinal data from the Acute group 
suggests that there is increased inhibition during the subacute phase, which may help to 
explain some of the motor symptoms observed during this period of time following mTBI 
(Howell et al. 2013b; Howell et al. 2015). However, these data do not suggest a long-
term difference in inhibition, as there were no differences in the Chronic group compared 
to controls. Therefore, cortical inhibition may not explain the persistent symptoms of 
chronic mTBI. Future studies should address why symptoms persist in some individuals, 
but not others, as well as the time course for changes in neurochemical activity following 
mTBI in humans  
Conclusion 
 We have shown that while cortical excitability does not seem to be altered acutely 
following mTBI, intracortical inhibition remains elevated into the subacute phase 
following mTBI. In individuals with chronic symptoms from mTBI, excitability was 
significantly different form healthy controls. While the Chronic group displayed lower 
cortical excitability compared to controls, no differences in intracortical inhibition in this 
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group were reported. Further research is needed to investigate the neurotransmitters 
responsible for TMS measures of cortical excitability and inhibition. 
Bridge to Chapter III 
  In Chapter II, alterations in motor cortex excitability were identified in individuals 
with chronic symptoms from mTBI, but there were no differences in cortical inhibition 
following mTBI. In Chapter III, potential differences in the neurotransmitters responsible 
for the TMS measures of excitability and inhibition, glutamate and GABA, are examined 




GLUTAMATE AND GABA CONCENTRATIONS FOLLOWING MTBI 
Some material from this chapter was accepted for publication in June 2018 in the 
Journal of Neurophysiology. Alia Yasen contributed to the concept of the study, recruited 
participants, collected and analyzed data, and helped prepare the initial manuscript. Dr. 
Jolinda Smith programmed the MRI functional localizer scan and provided support for 
the magnetic resonance spectroscopy sequences. Dr. Anita Christie contributed to the 
concept of the study, aided in the interpretation of the data, and critically reviewed and 
revised the manuscript.  
Introduction 
Mild traumatic brain injury (mTBI) is classified as an injury to the brain caused 
by mechanical force acting on the body (McCrory et al. 2013). It can lead to cognitive 
symptoms such as impaired memory, confusion, difficulty concentrating (Cantu 2006) 
and deficits in physical function such as slow movement speed (Gray et al. 1998), 
impaired balance (Chou et al. 2004), and slowed reaction time (Howell et al. 2013a). 
Widespread changes in metabolite concentration are a likely candidate to explain 
physical symptoms post-mTBI (Henry et al. 2010).  
Work in rodent models of mTBI suggests that immediately after a mechanical 
injury to the head, the brain enters a state of excitation as excitatory neurotransmitters, 
such as glutamate, are released (Giza and Hovda 2001). Glutamate transport decreases 
following mTBI, allowing excess glutamate to stay in the synapse and prolong the 
excitotoxic environment in the brain. In the rodent TBI model, the glutamate transporter 
GLUT-1 remains down-regulated up to 7 days post-injury (Cantu et al. 2015). This event, 
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and the resulting changes in metabolic environment in the brain that follow, is known as 
the Neurometabolic Cascade.  
Following the initial excitatory phase, an inhibitory, “spreading depression” phase 
occurs as the brain attempts to maintain homeostasis (Giza and Hovda 2001). Studies 
show that neurons injured following mTBI demonstrate a reduction in dendrite length and 
inhibited neuronal signaling, suggesting that mTBI may lead to a change in the 
excitatory/inhibitory balance post-injury (Brizuela et al. 2017). Indirect evidence from 
transcranial magnetic stimulation studies suggests the potential for similar alterations in 
neurotransmitters in humans, as cortical excitability and inhibition have been shown to be 
altered following mTBI (Livingston et al. 2010; Miller et al. 2014). However, studies 
involving direct measurements of neurotransmitters in humans are limited.  
Proton magnetic resonance spectroscopy (
1
H-MRS) is a non-invasive, reliable 
(Yasen et al. 2017) technique that can be used to determine relative concentrations of 
target metabolites in vivo in the human brain. Using this technique, it has been shown 
that, despite normal neuropsychological scores and anatomical MRI results, athletes with 
mTBI have altered neurometabolic profiles in comparison to controls (Henry et al. 2010). 
Specifically, these athletes were reported to have lower levels of glutamate, the primary 
excitatory neurotransmitter, in the primary motor cortex (M1). Measures of GABA, the 
primary inhibitory neurotransmitter, have not shown to be different in M1 post-mTBI 
(Tremblay et al. 2014). These previous studies, however, involved measurements taken 
from those with acute injury (Henry et al. 2010) and asymptomatic controls (Tremblay et 
al. 2014). Assessments from individuals with chronic symptoms from mTBI will 
substantially enhance our understanding of the neurophysiological recovery from mTBI.  
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The purpose of this study, therefore, was to determine concentrations of glutamate 
and GABA in the brain acutely after mTBI and in those who experience chronic 
symptoms (≥3 months) following mTBI. It was hypothesized that these concentrations 
would follow a pattern similar to that of rodent models, with higher concentrations of 
excitatory neurotransmitters acutely post-injury and higher concentrations of inhibitory 
neurotransmitters in those with chronic symptoms from mTBI.  
Materials and methods 
Participants 
 Fifty-three individuals were assigned to one of four groups: (i) without history of 
mTBI (Control, n=11, 6 females), (ii) within 72-hours of diagnosis of mTBI (Acute, n=9, 
5 females), (iii) with history of mTBI and no remaining symptoms (Chronic Control, 
n=20, 10 females), and (iv) with chronic symptoms from mTBI, lasting at least 3 months 
post-injury (Chronic, n=13, 6 females). All injuries met the definition of concussion 
provided by the 4
th
 International Consensus Statement on Concussion in Sport (McCrory 
et al. 2013). All participants provided written informed consent and were asked to 
complete a brief medical history and TMS safety screening questionnaire to determine 
eligibility to participate before enrollment. 
Exclusion criteria for all participants included: 1) history of cognitive 
deficiencies, such as permanent memory loss or concentration abnormalities (unrelated to 
the mTBI injury), 2) loss of consciousness from the mTBI lasting more than one minute, 
3) history of attention deficit hyperactivity disorder, or 4) contraindications to the use of 
MRS.  All procedures were reviewed and approved by the University of Oregon 
Institutional Review Board prior to any data collection. Three individuals (one each from 
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the Control, Chronic Control, and Chronic groups) were excused from this portion of the 
study due to contraindications with MRS, leaving a total of 50 participants.  
Measurement schedule 
Each participant completed at least one testing session, during which measures of 
glutamate and GABA concentrations were obtained using proton magnetic resonance 
spectroscopy (
1
H-MRS) from the primary motor cortex (M1). 
1
H-MRS was performed in 
a 3T whole-body MR scanner (Skyra: Siemens, Erlagen, Germany) using a 32-channel 
receive-only phased-array head coil. Individuals in the acute mTBI group were tested 
within 72 hours of sustaining their injury (± 2 days).  Participants in the Chronic group 
were tested an average of 3.4 years post-injury (± 2.1 years), and those in the Chronic 
Control group were tested an average of years 4.3 years post-injury (± 2.9 years).    
A total of 9 Acute and 9 Control participants came in for additional testing. These 
acutely-injured individuals came in for three testing sessions, first, within 72 hours of 
injury, then again at 1 month and 2 months post-injury. The 9 Control participants 
followed a similar timeline, once recruited. 
Anatomical MRI images of the brain were acquired and reviewed by the MRI 
technologist, and no incidental findings or brain abnormalities were reported for any of 
the participating subjects.  
Functional localizer task 
  A functional localizer task was administered in order to place a voxel at M1. 
During the M1 localizer task, participants were asked to tap the index finger of their 
dominant hand on the MRI bed upon visual presentation of a target word. Participants 
alternated between tapping for 24 seconds and resting for 24 seconds for approximately 3 
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minutes. Once the localizer task was complete, a voxel measuring 20 × 20 × 20 mm was 
placed in the region activated by the localizer contrast representing M1 (Figure 3.1, left). 
 
Figure 3.1. Functional localizer scans for voxel placement and Glutamate and 
GABA sample spectra from M1. Left: M1 localizer scan (voxel size: 20×20×20 mm). 
Right: The area under glutamate (2.4 ppm; TR/TE=1500/30ms, 256 acquisitions) and 
GABA (3.0 ppm; TR/TE=2000/68ms, 128 acquisitions) peaks were calculated and 
expressed relative to total creatine. Target peaks for glutamate and GABA are indicated 
by an arrow. 
 
Glutamate and GABA estimation 
A 6-minute single-voxel PRESS sequence (TR/TE=1500/30ms, 256 acquisitions) 
(Henry et al. 2010) was used to assess glutamate and a 9-minute adapted MEGA-PRESS 
sequence for GABA (TR/TE=2000/68ms, 128 acquisitions) (Mullins et al. 2013). Sample 
spectra are shown in Figure 3.1., right. The area under glutamate (2.4 ppm) and GABA 
(3.0 ppm) peaks were calculated and expressed relative to total creatine using LCModel 
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(Provencher 1993). Creatine values did not change over time in M1 (p=0.25). Therefore, 
we are confident that any differences in metabolic ratios expressed over creatine between 
groups or over time are a result of changes in glutamate or GABA rather than creatine.   
Statistical analysis 
Two-factor repeated measures ANOVAs (mTBI group, time) were calculated for 
the sub-set of Acute and Control participants who came to lab for multiple days of 
testing. Unpaired t-tests were used to compare age, height, and weight between all four 
groups. One-factor (mTBI group) ANOVAs were used to assess differences in glutamate 
and GABA concentration between mTBI groups. Where necessary, post-hoc pairwise 
comparisons with Bonferroni adjustments were made.  
Results 
Participants 
 Participant characteristics are presented in Table 3.1. There were no group 
differences in height (p=0.21) or weight (p=0.28), but the Chronic group was 
significantly older than the other three groups (p=0.009). 
Table 3.1. Group Characteristics 
 Control Acute Ch. Cont. Chronic     p 
n 10 (6 f) 9 (5 f) 19 (10 f) 12 (6 f)  
Age (years) 21.1 ± 0.9 20.8 ± 2.3 20.6 ± 2.0 26.7 ±  9.5 0.009 
Height (cm) 169.9 ± 10.7 174.4 ± 11.1 173.7 ± 8.3 164.6 ± 7.3 0.21 







For the subset of Acute and Control participants who participated in three sessions 
of testing over a 2-month recovery period, glutamate concentrations were similar between 
groups (p=0.70; Figure 3.2) but significantly different across time (p=0.03). While the 2-
week time point was slightly higher than the 72-hour time point, this difference did not 
reach statistical significant (p≥0.06).  Post-hoc analysis did not reveal a significant 
difference between any other time points (p≥0.10).  There was no significant interaction 
between group and time (p=0.13).  
 
Figure 3.2. Glutamate concentrations/creatine in M1 over time. Glutamate 
concentrations were similar between groups (p=0.70) and across time (p≥0.10).  There 










Glutamate/creatine values in M1 for all four groups are shown in Figure 3.3. 
Results from the ANOVA test indicated that glutamate/creatine values were similar 
between groups (p=0.93). 
 
Figure 3.3. Glutamate concentrations/creatine in M1. Glutamate/creatine 
concentrations were similar between groups (p=0.93).  
 
GABA 
GABA concentrations for the subset of Acute and Control participants were 
similar between groups (p=0.57; Figure 3.4) and across time (p=0.13). There was a 
significant interaction between group and time (p=0.05), however, post-hoc comparisons 
did not reveal any significant difference in GABA between groups at any of the three 




Figure 3.4. GABA concentrations/creatine in M1 over time. GABA concentrations 
were similar between groups (p=0.57) and across time (p=0.13). There was a significant 
interaction between group and time (p=0.05), however, post-hoc comparisons did not 
reveal any significant difference in GABA between groups at any of the three time points 
(p≥0.40).   
 
GABA/creatine values in M1 for all four groups are shown in Figure 3.5. Results 
from the ANOVA test indicated that GABA/creatine values were not quite statistically 
different between groups (p=0.06). Post-hoc analysis indicated that the trend for 
significance was between the Acute and Chronic groups, where the Chronic group had 






Figure 3.5. GABA concentrations/creatine in M1. Concentrations of GABA/creatine 
were not quite statistically different between groups (p=0.06).  
 
Discussion 
The purpose of this study was to determine concentrations of glutamate and 
GABA in the brain acutely after mTBI and in those with chronic symptoms (≥ 3 months) 
post-mTBI. These results suggest that individuals with mTBI have similar levels of 
glutamate and GABA in M1 compared with healthy controls, and these concentrations do 
not seem to change over time during recovery.  
 Evidence from animal studies suggests that the concentration of glutamate is 
higher in the brain immediately post-mTBI, but typically resolves within hours (Giza and 
Hovda 2001). In the current study we found no difference in concentrations of glutamate 
in M1in those with and without mTBI at any time point over a period of recovery. These 
results are similar to those of Tremblay et al., (2014), who found no difference in M1 
concentrations of glutamate in athletes 3 years after an mTBI. However, further 
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conflicting evidence suggests lower levels of glutamate in M1, in athletes with mTBI, 
one week post-injury (Henry et al. 2010). Taken together, the data from these studies 
suggest that potential changes in glutamate concentrations are highly dependent on the 
time post-injury and the time course of changes may be different for different regions of 
the brain. Further work is necessary to establish such a time course in humans. 
 Results from the present study suggest no differences in GABA concentration in 
M1 at any time point during a period of recovery from mTBI. Few 
1
H-MRS studies have 
recorded GABA concentrations post-mTBI, but Tremblay et al., (2014) found no 
differences in M1 GABA concentrations in their mTBI group 3 years post-injury. To our 
knowledge, no studies have reported GABA concentrations in individuals with chronic 
symptoms post-mTBI. Like glutamate, it is possible that changes in GABA 
concentrations in individuals post-mTBI may be region-specific.  
 One limitation with 
1
H-MRS is that this technique provides an assessment of the 
total concentrations of metabolites in the brain and is not capable of measuring intra- and 
extra-cellular volumes separately. Therefore, it is possible that differences in the release 
or action of neurotransmitters like glutamate and GABA may exist in individuals 





Differences in glutamate and GABA concentration in the brain post-mTBI did not 
follow the pattern typically seen in the animal literature. In humans, changes in glutamate 
and GABA concentrations in the brain may depend on the amount of time that has 
elapsed post-injury, and may be region-specific. 
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Bridge to Chapter IV  
In Chapters II and III, potential differences in TMS and MRS measures of cortical 
excitability and inhibition were investigated in individuals with mTBI. In Chapter IV 
potential differences in these same measures of excitability and inhibition in M1 in 
individuals with risk factors for prolonged recovery and poorer outcomes following 




RISK MODIFIERS FOR PROLONGED RECOVERY FOLLOWING MTBI  
This chapter contains unpublished co-authored material. Alia Yasen contributed 
to the concept of the study, recruited participants, collected and analyzed data, and helped 
prepare the initial manuscript. Dr. Geeta Eick designed the genotyping and PCR reaction 
protocols, and aided in the interpretation of the data. Dr. Kirstin Sterner contributed to the 
concept and design of the study. Dr. Anita Christie contributed to the concept of the 
study, interpretation of the data, and critically reviewed and revised the manuscript.  
Introduction 
 Numerous factors have been found to contribute to recovery from mTBI, and 
among the most extensively studied are the influence of sex and genetic factors that may 
predispose individuals to negative outcome following mTBI.  
Influence of sex on mTBI recovery 
Females now comprise 43% of the collegiate athlete population, an eightfold 
increase since Title IX went into effect in 1972 (Irick 2014). As the rate of female 
student-athlete participation in sports increases, a greater understanding of the role of sex 
in recovery from mTBI is needed.  
Mortality rates in individuals after mTBI have been shown to be significantly 
higher in females compared with males (Klauber et al. 1981; Farace and Alves 2000) 
despite the fact that males are more at-risk for sustaining mTBI (Broshek et al. 2005). 
While many studies report significantly poorer post-injury outcomes in females following 
mTBI, the overall findings are inconsistent. Some research suggests that females suffer 
from more severe outcomes after mTBI, including more post-injury symptoms (Covassin 
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et al. 2013), longer reaction times (Colvin et al. 2009), and more significant declines in 
cognitive function from baseline pre-injury levels (Broshek et al. 2005; Covassin et al. 
2013). However, other human and animals studies have reported no sex differences in 
recovery outcomes after mTBI (Zuckerman et al. 2012), and some have concluded that 
males have more long-lasting and severe cognitive outcomes than females (Groswasser et 
al. 1998).  
While changes in motor cortex function (addressed in Chapter II) have been 
reported in individuals with mTBI, very little is known about how mTBI may 
differentially affect motor cortex function in males and females. Assessing 
neurophysiological differences post-injury can provide valuable insights into potential 
sex-specific approaches to treatment.  
APOE and mTBI 
The APOE gene has received much attention from mTBI researchers in recent 
years, specifically in regards to the association between the ε4 allele with poorer outcome 
after TBI. Researchers have reported greater severity of injury (Jiang et al. 2011), worse 
Glasgow Coma Scale scores (Teasdale et al. 1997), lower motor scores on the Functional 
Independence Measure (Lichtman et al. 2000), and cognitive impairment in elderly and 
adolescent populations (Eramudgolla et al. 2014; Lawrence et al. 2015) in those 
individuals who possessed at least one ε4 allele in their genotype. Possession of one or 
more ε4 alleles is associated with a 10-fold increased risk of mTBI history in athletes 
(Tierney et al. 2010). Despite the relative rarity of the ε4 allele in nature, this isoform is 
overrepresented in chronic traumatic encephalopathy and chronic TBI populations 
(McKee et al. 2009).  
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The detrimental effects of the ε4 allele tend to occur in a dose-dependent fashion, 
meaning that the highest risks and poorest outcomes occur in those ε4 homozygotes who 
possess two ε4 alleles (ε4ε4 genotype) (Guo et al. 2000). It has been suggested that the ε4 
allele produces a less efficient apoE protein in astrocytes and microglia, and its 
inadequacy is exaggerated in an environment like TBI where its role is more heavily 
required for recovery (Lawrence et al. 2015).  
 Animal studies provide insight into the role of APOE genotype and levels of 
excitatory and inhibitory neurotransmitter concentration in the cortex. Chen et al. (2010) 
observed that ε4 carrier mice displayed reduced glutamate receptor function in the brain. 
Further, Dumanis et al., (2013) used magnetic resonance spectroscopy (MRS) and found 
decreased global concentrations of the excitatory neurotransmitter glutamate and 
increased levels of glutamine in the brains of ε4 carrier mice. In this study, concentrations 
of GABA, an inhibitory neurotransmitter, were not different among ε4 carriers. While the 
ε4 allele has been associated with alterations of glutamate and GABA in the rodent brain, 
the relationship between this risk factor and neurochemical changes following mTBI in 
humans remains unknown. 
Purpose 
The purpose of this study was to examine the potential influence of sex and 
genetic factors on neurophysiological recovery from mTBI. To accomplish this, two sub-
studies are included, one addressing each risk factor.  The aim of the first sub-study was 
to compare excitability and inhibition of the motor cortex in males and females with 
mTBI acutely following injury and throughout two months of recovery.  
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The aim of the second sub-study was to establish the difference in motor cortex 
function between apoε4 carriers and non-carriers. It was hypothesized that carriers would 
have lower levels of excitability and excitatory transmitter (glutamate) and similar levels 
of intracortical inhibition and inhibitory neurotransmitter (GABA) than non-carriers. 
Materials and methods 
Sub-study 1: The influence of sex on motor cortex function following mTBI 
Participants 
Twenty individuals (ages 21.2 ± 4.4 years; 10 female) who had suffered mTBI 
and 20 control individuals participated in this study. Individuals in the mTBI group were 
diagnosed by health professionals (physician or athletic trainer) as having a mild 
traumatic brain injury and reported to the laboratory within 72 hours post-injury. Of the 
20 mTBIs sustained, 8 were sports-related and included injuries sustained from playing 
rugby (4), soccer (2), wrestling (1), and basketball (1). The 12 non-sports-related mTBIs 
were sustained as a result of bicycle accidents (4), household accidents (4), falls (3), and 
motor vehicle accidents (1).  Eight individuals in the mTBI group had history of at least 
one previous mTBI. No other injuries requiring medical attention were reported. The 
control participants were age-, height-, weight-, sex-, and activity-matched to each 
concussed participant. Exclusion criteria included (1) a previous mTBI within a year 
prior to testing or two or more mTBIs prior to one year before testing, (2) loss of 
consciousness (LOC) for more than one minute (mTBI group), (3) history of cognitive 
deficiencies including memory loss or difficulty concentrating, (4) history of attention-
deficit hyperactivity disorder, seizures, musculoskeletal impairments, neurological 
impairments, or (5) contraindications to the use of TMS. All participants completed a 
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brief medical history and TMS safety screening questionnaire (Wasserman 1998) to 
determine their eligibility to participate. Participants in the mTBI group who experienced 
a loss of consciousness for greater than 1 minute were excluded because of the role that 
prolonged LOC plays in mTBI management modification (McCrory et al. 2013). All 
procedures were reviewed and approved by the Institutional Review Board at the 
University of Oregon and written informed consent was obtained prior to testing.  
Testing Protocol 
 All participants completed 5 testing sessions, during which measures of cortical 
excitability and inhibition were obtained from the first dorsal interosseous (FDI) muscle 
of the dominant hand. All participants with mTBI were tested within 72 hours of 
sustaining their injury, and on four subsequent visits at: one week, two weeks, one month, 
and two months post-injury. Control participants followed a similar timeline.  
Symptom inventory 
 Prior to each testing session, all participants completed a 22-item symptom 
inventory adopted from the IMPACT grading scale(McCrory et al. 2009) and the 
recommendations outlined in a 2005 consensus statement (McCrory et al. 2005). Severity 
of symptoms was rated on a 6-point Likert scale and summed across items to yield an 
overall score out of 132, with higher scores indicating worse symptoms. 
Electromyography (EMG) 
 EMG activity was recorded with surface electrodes placed over the FDI muscle of 
the dominant hand. Prior to electrode placement, the skin over the FDI was cleaned to 
reduce signal impedance. A preamplified bipolar Ag-AgCl electrode (DE-2.1, Delsys 
Inc., Boston, MA), with an inter-electrode distance of 1 cm was connected to a portable 
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amplifier (Delsys Inc., Boston, MA), which further amplified and band-pass (20-450 Hz) 
filtered the EMG signal. A ground electrode was secured to the posterior aspect of the 
distal ulna. The EMG signal was sampled at 5kHz with a 16-bit A/D converter (NI USB-
6251, National Instruments, Austin, TX) and stored for off-line analysis (Data 
Acquisition System Laboratory, DasyTec, USA Inc., Amherst, NH).  At the beginning of 
each testing session, subjects performed two maximum voluntary contractions (MVCs), 
and the highest EMG amplitude of the two was recorded as their maximum. 
Resting Motor Threshold (RMT) and Motor evoked potential (MEP) 
 Transcranial magnetic stimulation (TMS) was performed using a flat 70-mm 
figure-of-eight coil (Magstim 200, Magstim Ltd., Carmarthenshire, UK) positioned over 
the optimal site of the contralateral motor cortex to elicit MEPs in the dominant FDI. 
Once the optimal site was located, the RMT was determined as the lowest intensity 
required to evoke a response of at least 50µV in at least 5 out of 10 trials (Orth and 
Rothwell 2004; Werhahn et al. 1999). The stimulus intensity was decreased or increased 
in increments of 1 or 2% of stimulator output until an intensity that met the threshold 
criteria was found, while stimulation at 1% of stimulator output below that intensity did 
not meet the threshold criteria. Five stimuli were then delivered at an intensity of 120% 
of RMT to evoke MEPs with at least a 10 second inter-stimulus interval. Five 
stimulations have been shown to be sufficient to obtain reliable MEP amplitudes (Christie 
et al. 2007). These trials were recorded for offline analysis.  
Cortical silent period (CSP) 
 Cortical silent periods were evoked by five single-pulse stimulations delivered at 
120% of the RMT while participants maintained a voluntary isometric muscle contraction 
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of the dominant FDI at 50% of their maximum. Visual feedback of EMG activity was 
provided on an oscilloscope with target lines positioned at 50% of MVC. Five trials were 
completed with a rest period of 10-15 seconds between stimulations.  
Data analysis 
 Sample recordings of an MEP and CSP are shown in Figure 2.1. All processing 
was completed by the same trained investigator, using custom programs written in 
Matlab software (Mathworks Inc., Natick, MA). The peak-to-peak amplitude of the MEP 
was determined by marking the onset and offset of the muscle response and calculating 
the magnitude of the range between the highest and lowest EMG value in the selected 
period. The CSP duration was manually determined as the time between the conclusion 
of the MEP and the resumption of voluntary EMG activity. Manual selection of EMG 
onset and offset times has been shown to be highly reliable when performed by the same 
experimenter (Ives and Wigglesworth 2003), and is a standard, reliable method for 
determining CSP duration (Kimberley et al. 2009). MEP amplitude and CSP duration 
were then averaged across the five trials of each measure for each participant. 
Experimenters were blinded to participant status during data analysis. 
Statistical analysis 
 Two factor (group, sex) ANOVAs were performed to examine differences across 
groups in the descriptive characteristics of age, height and weight. Three-way repeated 
measures ANOVAs were performed to determine the effect of sex (female vs. male), 
group (mTBI vs. controls), time (72 hours, one week, two weeks, one month, and two 
months), and interaction effects for Symptom Score, RMT, MEP amplitude, and CSP 
duration. Post-hoc pairwise comparisons with Bonferroni correction were performed for 
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significant interactions. Data are presented as mean±SEM. Effect sizes (Cohen’s d) were 
calculated for the main effect of group and sex for RMT, MEP amplitude, and CSP 
duration. For all TMS measures, coefficients of variation were calculated to determine 
inter- and intra-subject variability. 
Sub-study 2: The influence of APOE genotype on motor cortex function following mTBI 
Participants 
Fifty-two participants between the ages of 18 and 60 participated in this study. 
Exclusion criteria for all participants included: 1) history of cognitive deficiencies, such 
as permanent memory loss or concentration abnormalities 2) history of attention deficit 
hyperactivity disorder, or 3) contraindications to the use of TMS or MRS.  All procedures 
were reviewed and approved by the University of Oregon Institutional Review Board 
prior to any data collection. A total of 35 individuals consented to participate in both the 
TMS and MRS portions of the study, 16 participated in TMS only, and one individual 
participated in the MRS protocol only.  
 Of the fifty-two participants who provided saliva samples for genotyping, samples 
for twenty-three participants were collected remotely and mailed to the laboratory by the 
participant. These participants had previously completed the TMS and /or MRS protocol 
1-5 years prior and agreed to provide a sample upon being contacted. These individuals 
used the same DNA self-collection kits as the participants who provided a sample on the 
day of testing.  
APOE genotype 
 All participants provided a saliva sample for genotyping using the Oragene OG-
500 Self-Collection kits (DNA Genotek, Ontario, Canada). The saliva was stored at room 
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temperature and the DNA extracted according to the manufacturer guidelines and 
standard methodology. Genomic DNA was quantified using a Qubit 2.0 Fluorometer. 
Genotyping was performed on an Applied Biosystems StepOne Plus Real-time PCR 
machine using two predesigned Applied Biosystems TaqMan SNP Genotyping Assays 
(C-3084793-20 and C-904973-10) that targeted the APOE SNPs of interest (rs429358 
and rs7412, respectively) (Applied Biosystems, Foster City, California). Briefly, 12.5 ng 
of DNA was added to an 8-strip tube containing 13.75 μl of master reaction mix (12.5 μl 
2× TaqMan Universal PCR Master Mix, and 1.25 μl 20× assay mix) along with negative 
(no template) controls in a final volume of 25 μl.  
Measurement schedule 
  Participants completed one session of TMS and/ or one session of MRS, during 
which measures of motor cortex excitability and inhibition were obtained using TMS, 
and measures of glutamate and GABA concentrations were obtained using proton 
magnetic resonance spectroscopy (
1
H-MRS) from the primary motor cortex (M1). 
Electromyography (EMG) 
 A preamplified bipolar, Ag-AgCl EMG electrode (DE-2.1, Delsys Inc., Boston, 
MA), with an inter-electrode distance of 1 cm was placed over the first dorsal 
interosseous (FDI) of the dominant hand. This electrode was connected to a portable 
amplifier (Delsys Inc., Boston, MA), which further amplified and band-pass (20-450 Hz) 
filtered the EMG signal. A ground electrode was secured to the posterior aspect of the 
distal ulna. The EMG signal was sampled at 5 kHz with a 16-bit A/D converter (NI USB-
6251, National Instruments, Austin, TX).  
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Motor evoked potential (MEP) and Cortical Silent Period (CSP) 
 TMS was performed using a flat, 70-mm figure-of-eight coil positioned over the 
optimal site of the contralateral motor cortex to elicit motor evoked potentials (MEP) in 
the dominant FDI. The optimal site was defined as the position that yielded the largest 
MEP consistently. Once the optimal site was located, the resting motor threshold (RMT) 
was determined as the lowest intensity required to evoke a response of at least 50µV in at 
least 5 out of 10 trials (Orth and Rothwell 2004; Werhahn et al. 1999). Eight cortical 
silent periods were then evoked by single-pulse stimulations delivered at 120% of the 
RMT while participants maintained an isometric of the dominant FDI at 50% of their 
maximal voluntary contraction (MVC). Visual feedback, including a target line at 50% 
MVC, was provided to the participants and the experimenter ensured that participants had 
reached the target level of EMG prior to providing the TMS pulse. A rest period of 30 
seconds was provided between stimulations.  
 Motor cortex excitability was assessed through the peak-to-peak amplitude of the 
active MEP (Figure 2.1, horizontal lines). Inhibition was assessed through the CSP 
duration and was manually identified for each trial as the time between the end of the 
MEP and the resumption of voluntary EMG activity (Figure 2.1, shaded area). All trials 
were analyzed, using a custom-written MATLAB (Mathworks Inc., Natick, MA) 
program, by the same trained investigator, who was blinded to the participants’ group at 
the time of data analysis. Such manual selection of EMG onset times has been shown to 




Functional localizer task 
  A functional localizer task was administered in order to place a voxel at M1. 
During the M1 localizer task, participants were asked to tap the index finger of their 
dominant hand on the MRI bed upon visual presentation of a target word. Participants 
alternated between tapping for 24 seconds and resting for 24 seconds for approximately 3 
minutes. Once the localizer task was complete, a voxel measuring 20 × 20 × 20 mm was 
placed in the region activated by the localizer contrast representing M1 (Figure 3.1, left). 
Glutamate and GABA estimation 
A 6-minute single-voxel PRESS sequence (TR/TE=1500/30ms, 256 acquisitions) 
(Henry et al. 2010) was used to assess glutamate and a 9-minute adapted MEGA-PRESS 
sequence for GABA (TR/TE=2000/68ms, 128 acquisitions) (Mullins et al. 2013). Sample 
spectra are shown in Figure 3.1., right. The area under glutamate (2.4 ppm) and GABA 
(3.0 ppm) peaks were calculated and expressed relative to total creatine using LCModel 
(Provencher, 1993). Creatine values did not change over time in M1 (p=0.25). Therefore, 
we are confident that any differences in metabolic ratios expressed over creatine between 
groups or over time are a result of changes in glutamate or GABA rather than creatine.   
Statistical analysis 
 Unpaired t-tests were used to compare age, height, weight, motor evoked potential 
(MEP) amplitude, cortical silent period (CSP) duration, glutamate concentration, and 







 Participant characteristics are presented in Table 4.1. There were no significant 
differences in age (F1,38=1.48; p>0.24) or weight (F1,38=0.002; p>0.10) across groups. 
Males were significantly taller than females (F1,38=48.44; p=0.0001).  









n 10 10 10 10 
Age (years) 20.2 ± 0.63 22.1 ± 1.86 20.6 ± 0.56 22.1 ± 2.02 
Height (cm)† 165.1 ± 1.97 178.2 ± 2.13 164.6 ± 2.06 179.2 ± 1.99 
Mass (kg) 69.0 ± 5.91 73.3 ± 3.63 66.7 ± 3.07 76.0 ± 3.28 
†Significant difference between males and females (p < 0.0001) 
 
Symptom inventory 
Figure 4.1 displays the results for symptom score. Symptom scores were higher 
overall in the mTBI group compared with controls (F1,35=16.82; p<0.001; d=1.09) and 
decreased over time (F4,140=19.74; p<0.001). A significant group-by-time interaction was 
observed (F4,140=18.96; p<0.001), suggesting that the groups changed differently over 
time. Specifically, symptom scores were higher in the mTBI group than the controls at 
the 72 hour, one week, and two week time points (p≤0.04) with no differences between 
groups at the 1 month or 2 month time point (p≥0.20). There was no significant main 
effect of sex (F1,35=1.53; p=0.22; d=0.30) and no significant group by sex interaction 
(F1,35=0.94; p=0.34). However, the time-by-sex interaction was significant (F4,140=2.61; 
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p=0.04), as females had higher symptom scores than males at the 72-hour time point 
(p=0.05). There were no differences between sexes at any other time point (p≥0.13).  
 
Figure 4.1. Symptom score. Symptom scores were higher overall in the concussed 
group compared with controls (p<0.001) and decreased over time (p<0.001). There was a 
significant group-by-time (p<0.001) and sex-by-time interaction (p=0.04). *Significant 
difference between concussed and control participants (p≤0.01). †Significant difference 
between males and females (p=0.05). 
 
Resting motor threshold (RMT) 
 Figure 4.2 shows the data for RMT. There were no significant effects of group 
(F1,35=1.31; p=0.26; d=0.28), sex (F1,35=0.01; p=0.91; d=0.01), or time (F4,140=1.22; 
p=0.31) on RMT.  There was a significant group-by-time interaction (F4,140=3.94; 
p=0.005), as RMT values were higher in the mTBI group at 72 hours post-injury 
(p=0.02), but were similar to controls at all other time points (p≥0.74). The group-by-sex 
(F1,35=0.59; p=0.45) and time-by-sex (F4,140=1.41; p=0.24) interactions were not 
significant, indicating similar changes in RMT in males and females over time. Inter-
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subject variability for RMT was low (CV=0.16), as was intra-subject variability across 
the 5 testing times for the mTBI group (CV=0.12; 0.10) and control (CV=0.08; 0.09) 
females and males, respectively.  
 
Figure 4.2. Resting motor threshold. There were no significant effects of group 
(p=0.26), sex (p=0.91), or time (p=0.31) on RMT.  There was a significant group by time 
interaction (p=0.005).  The group-by-sex (p=0.45) and time-by-sex (p=0.24) interactions 
were not significant. *Significant difference between concussed and control participants 
(p=0.02).  
 
Motor evoked potential (MEP) 
 The results for MEP amplitude are shown in Figure 4.3. There were no significant 
effects of group (F1,34=1.04; p=0.31; d=0.17), sex (F1,34=0.05; p=0.82, d=0.08), or time 
(F4,136=1.56; p=0.33) on MEP amplitude The group-by-sex (F1,34=0.13; p=0.72) and time-
by-sex (F4,136=0.51; p=0.73) interactions were also not significant. Inter-subject 
variability for MEP amplitude was high (CV=0.82), as was intra-subject variability for 
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the mTBI group (CV=0.62; 0.63) and control (CV=0.61; 0.58) females and males, 
respectively. 
 
Figure 4.3. MEP amplitude throughout recovery. There were no significant effects of 
group (p=0.31), sex (p=0.82), or time (p=0.33) on MEP amplitude. The group–by-sex 
(p=0.72) and time–by-sex (p=0.73) interactions were not significant. 
 
CSP Duration 
  Results for CSP duration are displayed in Figure 4.4. There were no significant 
effects of group (F1,35=1.50; p=0.23; d=0.31), sex (F1,35=2.84; p=0.10; d=0.41), or time 
(F4,140=1.03; p=0.39) on CSP duration. The interactions between group and sex 
(F1,35=0.04; p=0.84) and time and sex (F4,140=2.03; p=0.09) were also not significant. 
Inter-subject variability for CSP duration was low (CV=0.28), as was intra-subject 
variability for the mTBI group (CV=0.22; 0.17) and control (CV=0.23; CV=0.18) 
females and males, respectively.   
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Figure 4.4. CSP duration throughout recovery. There were no significant effects of 
group (p=0.23), sex (p=0.10), or time (p=0.39) on CSP duration. The group–by-sex 
(p=0.84) and time–by-sex (p=0.09) interactions were not significant.   
Sub-study 2 
Participants 
Participant characteristics are presented in Table 4.2. There were no group 
differences in height (p=0.87), weight (p=0.93), or age (p=0.45). 
Table 4.2. Group Characteristics (APOE Genotype) 
 Non-carrier ε4 Carrier        p 
n 40 (25f) 12 (5f)  
Age (years) 21.0 ± 2.3 21.8 ± 5.5 0.45 
Height (cm) 173.5 ± 9.9 174.2 ± 8.9 0.87 
Mass (kg) 71.9 ± 16.5 72.4 ± 12.7 0.93 
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Genotype frequencies are presented in Table 4.3. There were a total of 40 non-
apoε4 carriers and 12 carriers of the apoε4 allele. One carrier had the genotype ε2/ε4 and 
was excluded from the TMS and MRS analyses. This is standard procedure, as the ε2 
allele exhibits protective effects that are thought to oppose the effects of the ε4 allele 
(Hostage et al. 2013). 
Table 4.3. Genotype Frequencies 
Genotype n 
ε2/ ε2 1 (0f) 
ε2/ ε3 4 (4f) 








Table 4.4 shows the distribution of APOE genotype across mTBI group. 
Participants were categorized into one of four groups:  (i) without history of mTBI 
(Control), (ii) within 72-hours of diagnosis of mTBI (Acute), (iii) with history of mTBI 
and no remaining symptoms (Chronic Control), and (iv) with chronic symptoms from 
mTBI, lasting at least 3 months post-injury (Chronic). 
Table 4.4. APOE Genotype Across mTBI Group 
 Total samples Total ε4 carriers  Percent carrier 
Control 11 (5f) 2 (1f) 18% 
Acute 14 (9f) 3 (0f) 21% 
Chronic Control 21 (10f) 4 (2f) 19% 




Motor evoked potential and cortical silent period 
 There was no significant difference in MEP amplitude (p=0.19; Figure 4.5, left) 
or CSP duration (p=0.96; Figure 4.5, right) between groups.   
 
Figure 4.5. MEP amplitude and CSP duration. MEP amplitude was not significantly 
different between groups (p=0.19). CSP duration was not significantly different between 
groups (p=0.96).  
 
Glutamate and GABA concentrations 
 There were no differences in glutamate/creatine concentrations (p=0.95; Figure 




Figure 4.6. Glutamate and GABA concentrations in M1. Glutamate concentration was 
not significantly different between groups (p=0.95). GABA concentration was not 
significantly different between groups (p=0.90).  
 
Discussion 
 The purpose of this study was to examine the potential influence of sex and 
genetic factors on neurophysiological recovery from mTBI. Despite differences in 
recovery of symptoms between males and females, we did not observe any sex-related 
differences in excitability or inhibition of the motor cortex. Results from this study also 
suggest that motor cortex function, as assessed by TMS measures of excitability and 
inhibition, and MRS measures of excitatory and inhibitory neurotransmitter is similar in 
those who possess an apoε4 allele and those who do not. 
Influence of sex on motor cortex function  
We found that RMT values were significantly higher in the mTBI group at 72 
hours post-injury, indicating lower levels of motor cortex excitability relative to the 
control group in both males and females. To our knowledge, this is the first study to 
provide a sex-based comparison of motor cortex excitability following mTBI. At all time 
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points beyond 72 hours, RMT decreased to control levels in both sexes, suggesting 
similar recovery in males and females. Although some reports suggest no difference in 
RMT acutely following mTBI (De Beaumont et al. 2007), our results are in agreement 
with reports demonstrating an acute reduction in excitability (Miller et al. 2014; 
Chistyakov et al. 1999). Such an acute alteration of excitability is also in agreement with 
data from rodent models, suggesting ionic and metabolic changes resulting in 
hyperexcitability, which is thought to resolve within days post-injury (Giza and Hovda 
2001). We did not document any significant differences in RMT beyond the 72-hour 
testing point. Consistent with these results, additional studies involving sports related 
mTBI have indicated no differences in RMT weeks to months after injury (De Beaumont 
et al. 2007).  
MEP amplitude may also be affected by metabolic changes resulting in 
hyperexcitability (Di Lazzaro et al. 2003). We did not see a significant effect of sex on 
MEP amplitude, a finding consistent with previous literature reporting no difference in 
MEP amplitude between healthy males and females (Pitcher et al. 2003). We also did not 
find a difference in MEP amplitude between control and mTBI individuals, which is 
consistent with previous literature reporting no difference in MEP amplitude at 2 weeks 
to 30 years post-injury (De Beaumont et al. 2009; Miller et al. 2014). Together, these 
results suggest that any changes in cortical excitability are resolved similarly in males 
and females within approximately one-week, consistent with the neurometabolic changes 
documented in rodent models (Clarkson et al. 2010). 
Previous studies have shown that CSP duration is longer in  individuals with 
mTBI compared with controls (De Beaumont et al. 2009; Miller et al. 2014), indicating 
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greater inhibition. Contrary to these previous reports (De Beaumont et al. 2009; Miller et 
al. 2014), we did not find any significant differences in inhibition between individuals 
with mTBI and control participants. Previous work has cited injury severity and number 
of previous mTBIs as factors explaining motor cortex dysfunction (De Beaumont et al. 
2007). It is possible that the injuries sustained in our mTBI group, which excluded 
moderate and severe injuries, as well as a history of two or more mTBIs, were not severe 
enough to detect a difference in motor cortex inhibition.  
Although there were no apparent sex differences in motor cortex excitability or 
inhibition, we did demonstrate a difference in recovery of symptoms. Participants with 
mTBI initially reported significantly more symptoms than the control group, but their 
symptoms resolved by two weeks post-injury. While the main effect of sex on symptom 
score was not significant, the significant time by sex interaction indicated that males and 
females recovered from symptoms differently. Females had significantly greater 
symptom scores than males at the 72-hour time point, with no differences by one week 
post-injury. Our observation of a sex-based difference in recovery of self-reported 
symptoms, but not measures of cortical excitability and inhibition, suggests that recovery 
of symptoms and cortical function may involve different physiological processes. Our 
data suggest that the metabolic changes (Giza and Hovda 2001) that would alter cortical 
excitability and inhibition may be similar between men and women, while additional 
factors contributing to symptoms may be different between sexes. Although there is no 
clear consensus on the reason for poorer post-injury outcomes in females, factors such as 
hormone levels, neck musculature, and overall cerebral organization have been suggested 
as contributors (Roof and Hall 2000; Andreason et al. 1994; Eckner et al. 2014). These 
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results provide indirect evidence for a similar neurometabolic response in males and 
females following mTBI and suggest that neurophysiological function does not likely 
contribute to the sex-based difference in symptom recovery.   
Influence of APOE on motor cortex function  
To our knowledge, this is the first study to compare motor cortex function 
between human carriers and non-carriers of the apoε4 allele. While previous studies have 
reported lower concentrations of glutamate in the brains of rodent apoε4 carriers 
(Dumanis et al. 2013), we did not report any differences in glutamate or motor cortex 
excitability between groups. It is possible that humans do not exhibit the decreased 
glutamate receptor function seen in animal carriers. It is also possible that differences in 
glutamate concentration may not be region-specific, as Dumanis et. al (2013) reported 
these differences in glutamate concentration globally in rodents, rather than in M1 
specifically. Similar to animal literature, we did not report any differences in GABA 
concentration or intracortical inhibition between carriers and non-carriers.  
 Similar to previous studies, the apoε4 allele was overrepresented in our 
participants with chronic symptoms from mTBI (McKee et al. 2009). While half of our 
participants in the Chronic group were found to be carriers of the apoε4 allele, the sample 
sizes of each group were too small to determine if this difference was significant between 
groups. More participants are needed in each group to determine if allele frequencies 
significantly differ from Hardy-Weinberg proportions.   
Conclusion 
In these studies, we have demonstrated sex-based differences in symptoms scores, 
with no differences in cortical excitability or inhibition. Additionally, human carriers of 
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the apoε4 allele appear to have similar motor cortex function and concentrations of 
excitatory and inhibitory neurotransmitter than non-carriers.  
While sex and the apoε4 allele have been associated with differences in outcome 
following mTBI, these risk factors did not seem to affect the function of the human motor 
cortex in this group of participants. It is possible that additional risk factors not addressed 
in this study, such as age at injury or mTBI history, may influence motor cortex recovery 
following mTBI. Further studies and more participants are needed to systematically 
determine the physiological basis for sex-related and gene-related differences in recovery 




Summary of findings 
This dissertation represents a compilation of studies which are among the first to 
document motor cortex excitability, inhibition, glutamate, and GABA concentrations in 
individuals with acute and chronic symptoms from mTBI. The data suggest that motor 
cortex excitability may be lower in individuals with chronic symptoms from mTBI, but 
glutamate, the excitatory neurotransmitter responsible for measures of cortical 
excitability, was not significantly different from control levels following injury. 
Intracortical inhibition was higher in acutely-injured participants within 72 hours of 
injury and at specific time points throughout a 2-month recovery, despite GABA 
concentrations in the motor cortex being similar to control levels. The risk factors female 
sex and apoε4 genotype did not have an effect on motor cortex function in individuals 
with mTBI. Taken together, these TMS and MRS data suggest a possible functional 
change longitudinally following mTBI, despite an expected neurochemical profile.  
Research on the apoε4 allele in animal models has suggested that carriers of this 
allele may have lower levels of glutamate in the brain compared with non-carriers 
(Dumanis et al. 2013). In this investigation, however, neurotransmitter concentrations 
were not affected by APOE genotype. It is therefore possible that differences in the action 
of glutamate, rather than simply the concentration of glutamate as detected by 
1
H-MRS, 
exist in those ε4 carriers affected by mTBI. Indeed, it has been shown that glutamate 
receptors in ε4 rodent carriers are less effective than in non-carrier rodents (Chen et al. 
2010). Such a difference in receptor function, rather than total concentration of glutamate 
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may explain why individuals in our Chronic group (with a high percentage of ε4 carriers 
compared to other groups) demonstrated lower cortical excitability as assessed by the 
MEP amplitude, but similar concentrations of glutamate compared to healthy controls. 
Further research and more participants are necessary to determine if the lower levels of 
cortical excitability reported in the Chronic group were due to APOE genotype or some 
other factor related to their chronic mTBI.  
Very little is known about the association between GABA and the apoε4 allele. 
We found no relationship between intracortical inhibition, levels of GABA in M1, and 
the apoε4 allele. Our findings are similar to Dumanis et al. (2013), who found differences 
in glutamate function in rodent ε4 carriers, despite no differences in global GABA levels. 
It would be beneficial for future MRS studies to determine if the glutamate-to-GABA 
conversion is affected by the presence of the ε4 allele. 
Overall, results from these studies suggest that humans may not follow the same 
neurometabolic timeline as the rodent model following mTBI. It is likely that the TMS 
and MRS measures used to evaluate these changes in brain function following mTBI may 
not be ideal methods of determining the time course of a human Neurometabolic 
Cascade. Instead, measures sensitive to both the presence and action of neurometabolites 
in the brain should be taken from immediately following mTBI and throughout recovery. 
Caution should be taken when interpreting data from animal studies and applying to 
humans who have suffered mTBI. 
Limitations 
 Some factors may have limited the interpretation of the data in these studies. The 
majority of studies investigating neurochemical changes in the brain following TBI have 
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been conducted on animal models, often using post-mortem tissue samples. Human 
mTBI research presents a unique challenge, as it is impossible to control the impact and 
location of injury, and very difficult to monitor the time course of injury and recovery 
using TMS and MRS techniques. Although we excluded individuals from this study who 
were diagnosed with moderate or severe TBI, the exact location and mechanical impact 
of injury is difficult to monitor in human participants. Further, much of the research 
aiming to understand the recovery timeline of mTBI in humans relies on the brain-injured 
individual to accurately describe the method of injury and their symptoms following the 
event. Although participants were excluded from the study if they had experienced more 
than two diagnosed mTBIs in their lifetime, research suggests that repeated sub-
concussive blows may have a physiological influence as great as the impact of a 
diagnosed mTBI (Johnson et al. 2014). It is possible that control participants involved in 
a sport such as soccer may have had neurophysiological profiles more similar to those of 
the mTBI groups involved in this study. 
In the current investigation, the TMS measures of MEP amplitude and CSP 
durations were within normal ranges outlined in the literature (Oliviero et al. 2006; Sale 
and Semmler 2005). Although these have been documented to be reliable measures 
within participants across days (Edwards and Christie 2017), there was a high level of 
inter-individual variability with these measures, particularly the MEP. It is possible that 
this high level of variability may have reduced our ability to detect a statistically 





H-MRS studies are limited in that quantities of neurotransmitter are 
sampled from small regions of the brain. It is possible that, although rodent studies show 
global changes in the brain following mTBI, human may experience more region-specific 
changes. Further, in animal models, quantities of neurotransmitter are typically calculated 
from whole-brain histological samples post-mortem.   
Future research 
 Further study is required in order to understand the symptoms underlying acute 
and chronic mTBI, and why symptoms recover for some individuals following mTBI but 
not others. It would be ideal to establish baseline pre-injury measures from participants, 
and then follow up with those individuals who experience mTBI later in life. Such 
longitudinal studies, however, are costly and may take years to complete. Additionally, as 
the apoε4 allele is relatively rare among the population, more participants with this risk 
factor need to be recruited in order to compare the interaction between apoε4 carrier 
status and measures of motor cortex excitability, inhibition, and glutamate and GABA 
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